M&A Deal Summary

Thermo Fisher Scientific Acquires Olink

On October 17, 2023, Thermo Fisher Scientific acquired life science company Olink for 3.1B USD

Acquisition Highlights
  • This is Thermo Fisher Scientific’s 23rd transaction in the Life Science sector.
  • This is Thermo Fisher Scientific’s 7th largest (disclosed) transaction.
  • This is Thermo Fisher Scientific’s 2nd transaction in Sweden.

M&A Deal Summary
Date 2023-10-17
Target Olink
Sector Life Science
Buyer(s) Thermo Fisher Scientific
Deal Type Add-on Acquisition
Deal Value 3.1B USD
Advisor(s) J.P. Morgan Securities
Goldman Sachs (Financial)
Baker & McKenzie (Legal)

Target

Olink

Uppsala, Sweden
Olink provides leading solutions for advanced proteomics research and development, enabling biopharmaceutical companies and leading academic researchers to quickly and efficiently understand diseases at the protein level. Olink's proprietary technology, Proximity Extension Assay (PEA), enables high-throughput protein analysis for the very large installed base of qPCR and next-generation sequencing readout systems on the market. Olink was founded in 2016 and is based in Uppsala, Sweden.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Thermo Fisher Scientific

Waltham, Massachusetts, United States
Category Company
Founded 1956
Sector Test/Measurement Equipment
Employees122,000
Revenue 42.9B USD (2023)
DESCRIPTION
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.

Thermo Scientific is a provider of analytical instruments, laboratory equipment, software, services, consumables and reagents for better workflow solutions spanning sample preparation, sample analysis, and data interpretation. Thermo Fisher Scientific was founded in 1956 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 62 of 62
Sector (Life Science) 23 of 23
Type (Add-on Acquisition) 55 of 55
Country (Sweden) 2 of 2
Year (2023) 3 of 3
Size (of disclosed) 7 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-06 CorEvitas

Waltham, Massachusetts, United States

CorEvitas provides real-world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. Corona operates six major autoimmune registries across the US, Canada, and Japan, collecting data from over 500 participating investigator sites. CorEvitas was founded in 2001 and is based in Waltham, Massachusetts.

Buy $913M
Mergr

Product

Company

Legal